Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27626669 | 0.77 | — | — | |
| SCHEMBL19285040 | 0.77 | TSHR (0.35) | ALDH1A1TSHR | |
| SCHEMBL28073953 | 0.77 | ALDH1A1 (0.41) | ALDH1A1TSHR | |
| SCHEMBL27951067 | 0.77 | — | — | |
| SCHEMBL19285495 | 0.77 | TSHR (0.35) | ALDH1A1TSHR | |
| SCHEMBL2291884 | 0.77 | TSHR (0.35) | ALDH1A1TSHR | |
| SCHEMBL4902437 | 0.75 | ALDH1A1 (0.33) | ALDH1A1TSHR | |
| SCHEMBL8260413 | 0.75 | ALDH1A1 (0.33) | ALDH1A1TSHR | |
| SCHEMBL8117959 | 0.72 | ALDH1A1 (0.36) | ALDH1A1TSHR | |
| SCHEMBL2637176 | 0.72 | ALDH1A1 (0.35) | ALDH1A1TSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102753522-A | Substituted pyrrolidine-2-carboxamides | HOFFMANN LA ROCHE | 2012-10-24 | — | — | CN | disclosed |
| US-7498436-B2 | Substituted hydroxyethylamines | PHARMACIA & UPJOHN COMPANY LLC (US) | 2009-03-03 | — | — | US | disclosed |
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS AND PHARMACIA & UPJOHN COMPANY LLC | 2007-09-13 | — | — | US | disclosed |
| US-20060106256-A1 | Substituted hydroxyethylamines | PHARMACIA & UPJOHN COMPANY | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, CHAT | ALDH1A1 524/4885TSHR 3501/4885TP53 3792/4885 |
| US-20060106256-A1 | Substituted hydroxyethylamines | HNMT, PNMT, BCHE | ALDH1A1 589/4885TSHR 3738/4885TP53 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.